Association of IL-17A and IL-10 Polymorphisms with Juvenile Idiopathic Arthritis in Finnish Children
Abstract
:1. Introduction
2. Results
2.1. Characteristics of the Patient Population
2.2. IL-17A Polymorphisms
2.3. IL-10 Polymorphisms
2.4. IL-10 and IL-17 Haplotypes
2.5. The Role of IL-10 and IL-17 Polymorphisms in Disease Activity
2.6. The Effect of IL-17A and IL-10 Polymorphisms on Serum Cytokine Levels
3. Discussion
4. Material and Methods
4.1. Study Design and Subjects
4.2. Sampling and Data Collection
4.3. Genetic Analyses
4.4. Cytokine Measurements
4.5. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Petty, R.E. Growing pains: The ILAR classification of juvenile idiopathic arthritis. J. Rheumatol. 2001, 28, 927–928. [Google Scholar] [PubMed]
- Hersh, A.O.; Prahalad, S. Genetics of Juvenile Idiopathic Arthritis. Rheum. Dis. Clin. N. Am. 2017, 43, 435–448. [Google Scholar] [CrossRef]
- La Bella, S.; Rinaldi, M.; Di Ludovico, A.; Di Donato, G.; Di Donato, G.; Salpietro, V.; Chiarelli, F.; Breda, L. Genetic Background and Molecular Mechanisms of Juvenile Idiopathic Arthritis. Int. J. Mol. Sci. 2023, 24, 1846. [Google Scholar] [CrossRef] [PubMed]
- Kozlova, D.I.; Rybakov, A.V.; Yureva, K.A.; Khizha, V.V.; Sorokina, L.S.; Kostik, M.M.; Guslev, A.B. Specific Features of Juvenile Idiopathic Arthritis Patients’ Cytokine Profile. Biomedicines 2024, 12, 135. [Google Scholar] [CrossRef] [PubMed]
- Gutierrez-Arcelus, M.; Rich, S.S.; Raychaudhuri, S. Autoimmune diseases—Onnecting risk alleles with molecular traits of the immune system. Nat. Rev. Genet. 2016, 17, 160–174. [Google Scholar] [CrossRef] [PubMed]
- Koper-Lenkiewicz, O.M.; Sutkowska, K.; Wawrusiewicz-Kurylonek, N.; Kowalewska, E.; Matowicka-Karna, J. Proinflammatory Cytokines (IL-1, -6, -8, -15, -17, -18, -23, TNF-α) Single Nucleotide Polymorphisms in Rheumatoid Arthritis-A Literature Review. Int. J. Mol. Sci. 2022, 23, 2106. [Google Scholar] [CrossRef] [PubMed]
- Paroli, M.; Spadea, L.; Caccavale, R.; Spadea, L.; Paroli, M.P.; Nante, N. The Role of Interleukin-17 in Juvenile Idiopathic Arthritis: From Pathogenesis to Treatment. Medicina 2022, 58, 1552. [Google Scholar] [CrossRef]
- Hügle, B.; Horneff, G. The role of synthetic drugs in the biologic era: Therapeutic strategies for treating juvenile idiopathic arthritis. Expert Opin. Pharmacother. 2016, 17, 703–714. [Google Scholar] [CrossRef] [PubMed]
- Adrovic, A.; Yildiz, M.; Köker, O.; Şahin, S.; Barut, K.; Kasapçopur, Ö. Biologics in juvenile idiopathic arthritis-main advantages and major challenges: A narrative review. Arch. Rheumatol. 2021, 36, 146–157. [Google Scholar] [CrossRef]
- Fischer, J.; Dirks, J.; Haase, G.; Holl-Wieden, A.; Hofmann, C.; Girschick, H.; Morbach, H. IL-21+ CD4+ T helper cells co-expressing IFN-γ and TNF-α accumulate in the joints of antinuclear antibody positive patients with juvenile idiopathic arthritis. Clin. Immunol. 2020, 217, 108484. [Google Scholar] [CrossRef]
- Moore, K.W.; de Waal Malefyt, R.; Coffman, R.L.; O’Garra, A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 2001, 19, 683–765. [Google Scholar] [CrossRef]
- Wood, S.; Branch, J.; Vasquez, P.; DeGuzman, M.M.; Brown, A.; Sagcal-Gironella, A.C.; Singla, S.; Ramirez, A.; Vogel, T.P. Th17/1 and ex-Th17 cells are detected in patients with polyarticular juvenile arthritis and increase following treatment. Pediatr. Rheumatol. Online J. 2024, 22, 32. [Google Scholar] [CrossRef] [PubMed]
- Nistala, K.; Wedderburn, L.R. Th17 and regulatory T cells: Rebalancing pro- and anti-inflammatory forces in autoimmune arthritis. Rheumatology 2009, 48, 602–606. [Google Scholar] [CrossRef] [PubMed]
- Barnes, M.G.; Grom, A.A.; Thompson, S.D.; Griffin, T.A.; Pavlidis, P.; Itert, L.; Fall, N.; Sowders, D.P.; Hinze, C.H.; Aronow, B.J.; et al. Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. Arthritis Rheum. 2009, 60, 2102–2112. [Google Scholar] [CrossRef] [PubMed]
- Agarwal, S.; Misra, R.; Aggarwal, A. Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases. J. Rheumatol. 2008, 35, 515–519. [Google Scholar]
- Okeke, E.B.; Uzonna, J.E. The Pivotal Role of Regulatory T Cells in the Regulation of Innate Immune Cells. Front. Immunol. 2019, 10, 680. [Google Scholar] [CrossRef] [PubMed]
- de Waal Malefyt, R.; Abrams, J.; Bennett, B.; Figdor, C.G.; de Vries, J.E. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 1991, 174, 1209–1220. [Google Scholar] [CrossRef]
- Carter, N.A.; Rosser, E.C.; Mauri, C. Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis. Arthritis Res. Ther. 2012, 14, R32. [Google Scholar] [CrossRef]
- Finnegan, A.; Kaplan, C.D.; Cao, Y.; Eibel, H.; Glant, T.T.; Zhang, J. Collagen-induced arthritis is exacerbated in IL-10-deficient mice. Arthritis Res. Ther. 2003, 5, R18–R24. [Google Scholar] [CrossRef]
- Rezaei, E.; Hogan, D.; Trost, B.; Kusalik, A.J.; Boire, G.; Cabral, D.A.; Campillo, S.; Chédeville, G.; Chetaille, A.-L.; Dancey, P.; et al. Associations of clinical and inflammatory biomarker clusters with juvenile idiopathic arthritis categories. Rheumatology 2020, 59, 1066–1075. [Google Scholar] [CrossRef]
- Harjacek, M.; Diaz-Cano, S.; Alman, B.A.; Coburn, J.; Ruthazer, R.; Wolfe, H.; Steere, A.C. Prominent expression of mRNA for proinflammatory cytokines in synovium in patients with juvenile rheumatoid arthritis or chronic Lyme arthritis. J. Rheumatol. 2000, 27, 497–503. [Google Scholar] [PubMed]
- Sznurkowska, K.; Boćkowska, M.; Zieliński, M.; Plata-Nazar, K.; Trzonkowski, P.; Liberek, A.; Kamińska, B.; Szlagatys-Sidorkiewicz, A. Peripheral regulatory T cells and anti-inflammatory cytokines in children with juvenile idiopathic arthritis. Acta Biochim. Pol. 2018, 65, 119–123. [Google Scholar] [CrossRef] [PubMed]
- Scola, M.P.; Thompson, S.D.; Brunner, H.I.; Tsoras, M.K.; Witte, D.; Van Dijk, M.A.; Grom, A.A.; Passo, M.H.; Glass, D.N. Interferon-gamma:interleukin 4 ratios and associated type 1 cytokine expression in juvenile rheumatoid arthritis synovial tissue. J. Rheumatol. 2002, 29, 369–378. [Google Scholar] [PubMed]
- Crawley, E.; Kon, S.; Woo, P. Hereditary predisposition to low interleukin-10 production in children with extended oligoarticular juvenile idiopathic arthritis. Rheumatology 2001, 40, 574–578. [Google Scholar] [CrossRef] [PubMed]
- Kube, D.; Platzer, C.; von Knethen, A.; Straub, H.; Bohlen, H.; Hafner, M.; Tesch, H. Isolation of the human interleukin 10 promoter. Characterization of the promoter activity in Burkitt’s lymphoma cell lines. Cytokine 1995, 7, 1–7. [Google Scholar] [CrossRef] [PubMed]
- Eskdale, J.; Gallagher, G.; Verweij, C.L.; Keijsers, V.; Westendorp, R.G.; Huizinga, T.W. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc. Natl. Acad. Sci. USA 1998, 95, 9465–9470. [Google Scholar] [CrossRef] [PubMed]
- Turner, D.M.; Williams, D.M.; Sankaran, D.; Lazarus, M.; Sinnott, P.J.; Hutchinson, I.V. An investigation of polymorphism in the interleukin-10 gene promoter. Eur. J. Immunogenet. Off. J. Br. Soc. Histocompat. Immunogenet. 1997, 24, 1–8. [Google Scholar] [CrossRef]
- Müller, K.; Herner, E.B.; Stagg, A.; Bendtzen, K.; Woo, P. Inflammatory cytokines and cytokine antagonists in whole blood cultures of patients with systemic juvenile chronic arthritis. Br. J. Rheumatol. 1998, 37, 562–569. [Google Scholar] [CrossRef] [PubMed]
- Rioux, J.D.; Abbas, A.K. Paths to understanding the genetic basis of autoimmune disease. Nature 2005, 435, 584–589. [Google Scholar] [CrossRef]
- Espinoza, J.L.; Takami, A.; Nakata, K.; Onizuka, M.; Kawase, T.; Akiyama, H.; Miyamura, K.; Morishima, Y.; Fukuda, T.; Kodera, Y.; et al. A genetic variant in the IL-17 promoter is functionally associated with acute graft-versus-host disease after unrelated bone marrow transplantation. PLoS ONE 2011, 6, e26229. [Google Scholar] [CrossRef]
- Martini, A.; Lovell, D.J.; Albani, S.; Brunner, H.I.; Hyrich, K.L.; Thompson, S.D.; Ruperto, N. Juvenile idiopathic arthritis. Nat. Rev. Dis. Prim. 2022, 8, 5. [Google Scholar] [CrossRef]
- Lagström, H.; Rautava, P.; Kaljonen, A.; Räihä, H.; Pihlaja, P.; Korpilahti, P.; Peltola, V.; Rautakoski, P.; Österbacka, E.; Simell, O.; et al. Cohort profile: Steps to the healthy development and well-being of children (the STEPS Study). Int. J. Epidemiol. 2013, 42, 1273–1284. [Google Scholar] [CrossRef]
- Consolaro, A.; Bracciolini, G.; Ruperto, N.; Pistorio, A.; Magni-Manzoni, S.; Malattia, C.; Pederzoli, S.; Davì, S.; Martini, A.; Ravelli, A.; et al. Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score. Arthritis Rheum. 2012, 64, 2366–2374. [Google Scholar] [CrossRef]
- Consolaro, A.; Ruperto, N.; Bracciolini, G.; Frisina, A.; Gallo, M.C.; Pistorio, A.; Verazza, S.; Negro, G.; Gerloni, V.; Goldenstein-Schainberg, C.; et al. Defining criteria for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score. Ann. Rheum. Dis. 2014, 73, 1380–1383. [Google Scholar] [CrossRef]
- Vijatov-Djuric, G.; Doronjski, A.; Mitic, I.; Brkic, S.; Barisic, N. Interleukin-17A Levels Increase in Serum of Children With Juvenile Idiopathic Arthritis. Arch. Rheumatol. 2017, 32, 234–243. [Google Scholar] [CrossRef]
- Cardoso, I.; Frederiksen, P.; Specht, I.O.; Händel, M.N.; Thorsteinsdottir, F.; Heitmann, B.L.; Kristensen, L.E. Age and Sex Specific Trends in Incidence of Juvenile Idiopathic Arthritis in Danish Birth Cohorts from 1992 to 2002: A Nationwide Register Linkage Study. Int. J. Environ. Res. Public Health 2021, 18, 8331. [Google Scholar] [CrossRef]
- Berntson, L.; Gäre, B.A.; Fasth, A.; Herlin, T.; Kristinsson, J.; Lahdenne, P.; Marhaug, G.; Nielsen, S.; Pelkonen, P.; Rygg, M. Incidence of juvenile idiopathic arthritis in the Nordic countries. A population based study with special reference to the validity of the ILAR and EULAR criteria. J. Rheumatol. 2003, 30, 2275–2282. [Google Scholar]
- Shao, M.; Xu, W.; Yang, H.; Chen, Y.; Gao, X.; Xu, S.; Xu, S.; Shuai, Z.; Pan, F. Interleukin-17 Gene Polymorphism (Rs2275913 G/A, Rs763780 C/T) in Rheumatoid arthritis: Meta-analysis Based on Ethnicity. Immunol. Investig. 2021, 50, 685–699. [Google Scholar] [CrossRef]
- Chen, P.; Li, Y.; Li, L.; Zhang, G.; Zhang, F.; Tang, Y.; Zhou, L.; Yang, Y.; Li, J. Association between the interleukin (IL)-17A rs2275913 polymorphism and rheumatoid arthritis susceptibility: A meta-analysis and trial sequential analysis. J. Int. Med. Res. 2021, 49, 3000605211053233. [Google Scholar] [CrossRef]
- Zhang, M.; Peng, L.; Li, W.M.; Duan, Y.; Liu, X.M.; Chen, S.M.; Deng, J.; Liu, X. IL12B and IL17 genes polymorphisms associated with differential susceptibility to juvenile idiopathic arthritis and juvenile-onset systemic lupus erythematosus in Chinese children. Medicine 2023, 102, e34477. [Google Scholar] [CrossRef]
- Shen, L.; Zhang, H.; Yan, T.; Zhou, G.; Liu, R. Association between interleukin 17A polymorphisms and susceptibility to rheumatoid arthritis in a Chinese population. Gene 2015, 566, 18–22. [Google Scholar] [CrossRef]
- Priya, E.K.K.; Srinivas, L.; Rajesh, S.; Sasikala, K.; Banerjee, M. Pro-inflammatory cytokine response pre-dominates immuno-genetic pathway in development of rheumatoid arthritis. Mol. Biol. Rep. 2020, 47, 8669–8677. [Google Scholar] [CrossRef]
- Patrikiou, E.; Liaskos, C.; Mavropoulos, A.; Ntavari, N.; Gkoutzourelas, A.; Simopoulou, T.; Fechner, K.; Scheper, T.; Meyer, W.; Katsiari, C.G.; et al. Autoantibodies against specific nuclear antigens are present in psoriatic disease and are diminished by secukinumab. Clin. Chim. Acta 2020, 510, 400–407. [Google Scholar] [CrossRef]
- Fathy, M.M.; Elsaadany, H.F.; Ali, Y.F.; Farghaly, M.A.A.; Hamed, M.E.; Ibrahim, H.E.; Noah, M.A.; Allah, M.A.N.; Elashkar, S.S.A.; Abdelsalam, N.I.; et al. Association of IL-10 gene polymorphisms and susceptibility to Juvenile Idiopathic Arthritis in Egyptian children and adolescents: A case-control study. Ital. J. Pediatr. 2017, 43, 9. [Google Scholar] [CrossRef]
- Harsini, S.; Ziaee, V.; Maddah, M.; Rezaei, A.; Sadr, M.; Zoghi, S.; Moradinejad, M.H.; Tahghighi, F.; Aghighi, Y.; Rezaei, N. Interleukin 10 and transforming growth factor beta 1 gene polymorphisms in juvenile idiopathic arthritis. Bratisl. Lek. Listy 2016, 117, 258–262. [Google Scholar] [CrossRef]
- Jung, J.H.; Kim, J.-H.; Song, G.G.; Choi, S.J. Association between interleukin-10 polymorphisms and juvenile idiopathic arthritis: A meta-analysis. Minerva Pediatr. 2022, 74, 81–89. [Google Scholar] [CrossRef]
- Márka, M.; Bessenyei, B.; Zeher, M.; Semsei, I. IL-10 promoter -1082 polymorphism is associated with elevated IL-10 levels in control subjects but does not explain elevated plasma IL-10 observed in Sjögren’s syndrome in a Hungarian cohort. Scand. J. Immunol. 2005, 62, 474–480. [Google Scholar] [CrossRef]
- Hee, C.S.; Gun, S.C.; Naidu, R.; Gupta, E.; Somnath, S.D.; Radhakrishnan, A.K. Comparison of single nucleotide polymorphisms in the human interleukin-10 gene promoter between rheumatoid arthritis patients and normal subjects in Malaysia. Mod. Rheumatol. 2007, 17, 429–435. [Google Scholar] [CrossRef]
- Palmisani, E.; Solari, N.; Magni-Manzoni, S.; Pistorio, A.; Labò, E.; Panigada, S.; Martini, A.; Ravelli, A. Correlation between juvenile idiopathic arthritis activity and damage measures in early, advanced, and longstanding disease. Arthritis Rheum. 2006, 55, 843–849. [Google Scholar] [CrossRef]
- Schotte, H.; Schlüter, B.; Schmidt, H.; Gaubitz, M.; Drynda, S.; Kekow, J.; Willeke, P. Putative IL-10 Low Producer Genotypes Are Associated with a Favourable Etanercept Response in Patients with Rheumatoid Arthritis. PLoS ONE 2015, 10, e0130907. [Google Scholar] [CrossRef]
- Braga, M.; Lara-Armi, F.F.; Neves, J.S.F.; Rocha-Loures, M.A.; Terron-Monich, M.d.S.; Bahls-Pinto, L.D.; Neto, Q.A.d.L.; Zacarias, J.M.V.; Sell, A.M.; Visentainer, J.E.L. Influence of IL10 (rs1800896) Polymorphism and TNF-α, IL-10, IL-17A, and IL-17F Serum Levels in Ankylosing Spondylitis. Front. Immunol. 2021, 12, 653611. [Google Scholar] [CrossRef] [PubMed]
- Mu, J.; Xu, Y.; Zhu, H. AF4/FMR2 and IL-10 gene single nucleotide polymorphisms are correlated with disease susceptibility and immune infiltration in ankylosing spondylitis. Nan Fang Yi Ke Da Xue Xue Bao 2023, 43, 741–748. [Google Scholar] [CrossRef]
- Uusitupa, E.; Rahikkala, H.; Sard, S.; Pokka, T.; Salo, H.; Kärki, J.; Sokka-Isler, T.; Backström, M.; Vähäsalo, P. Incidence of juvenile idiopathic arthritis in Finland, 2000–2020. Rheumatology 2024. online ahead of print. [Google Scholar] [CrossRef] [PubMed]
- Auton, A.; Brooks, L.D.; Durbin, R.M.; Garrison, E.P.; Kang, H.M.; Korbel, J.O.; Marchini, J.L.; McCarthy, S.; McVean, G.A.; Abecasis, G.R.; et al. A global reference for human genetic variation. Nature 2015, 526, 68–74. [Google Scholar] [CrossRef]
- Vuononvirta, J.; Peltola, V.; Ilonen, J.; Mertsola, J.; He, Q. The Gene Polymorphism of IL-17 G-152A is Associated with Increased Colonization of Streptococcus pneumoniae in Young Finnish Children. Pediatr. Infect. Dis. J. 2015, 34, 928–932. [Google Scholar] [CrossRef]
- Gauderman, W.J. Sample size requirements for matched case-control studies of gene-environment interaction. Stat. Med. 2002, 21, 35–50. [Google Scholar] [CrossRef]
Juvenile Idiopathic Arthritis (JIA) Subtypes | |||||
---|---|---|---|---|---|
Parameter | All Patients, n = 98 (%) | Oligo Arthritis 1, n = 51 (%) | Polyarthritis, n = 34 (%) | ERA, n = 10 (%) | Other 2, n = 3 (%) |
Sex | |||||
Female | 71 (72.4) | 38 (74.5) | 29 (85.3) | 1 (10.0) | 3 (100.0) |
Male | 27 (27.6) | 13 (25.5) | 5 (14.7) | 9 (90.0) | 0 (0.0) |
Age of Diagnose (median, min – max, years) | 5.4 (1.0–14.9) | 5.3 (1.4–13.7) | 3.9 (1.0–14.9) | 11.4 (6.8–14.6) | 5.9 (3.7–12.6) |
Disease duration at time of sampling (min–max, years) | 2.9 (0–13.6) | 3.4 (0.0–13.6) | 3.9 (0.0–12.5) | 1.4 (0.2–4.2) | 1.0 (0.0–1.8) |
Medication 3 | |||||
DMAR only | 34 (34.7) | 18 (15.7) | 10 (29.4) | 4 (40.0) | 2 (66.7) |
Biologics only | 18 (18.4) | 9 (17.6) | 9 (26.5) | 0 (0.0) | 0 (0.0) |
DMARD and biologics | 34 (34.7) | 16 (31.4) | 14 (41.2) | 4 (40.0) | 0 (0.0) |
No medication | 12 (12.2) | 8 (15.7) | 1 (2.9) | 2 (20.0) | 1 (33.3) |
Disease activity 4,5 | |||||
Inactive (A) | 0 (0.0) | 0 (0.0) | 0 (0.0) | - | - |
Low activity (A) | 1 (1.7) | 1 (3.0) | 0 (0.0) | - | - |
Moderate activity(A) | 13 (22.4) | 3 (9.1) | 10 (40.0) | - | - |
High activity (A) | 44 (75.9) | 29 (87.9) | 15 (60.0) | - | - |
Missing data | 40 (40.8) | 18 | 9 | ||
Inactive (B) | 24 (32.4) | 14 (31.8) | 10 (33.3) | - | - |
Low activity (B) | 20 (27.0) | 9 (20.5) | 11 (36.7) | - | - |
Moderate activity (B) | 21 (28.4) | 13 (29.5) | 8 (26.7) | - | - |
High activity (B) | 9 (12.2) | 8 (18.2) | 1 (3.3) | - | - |
Missing data | 24 (24.5) | 7 | 4 | ||
Inactive (C) | 42 (53.2) | 24 (53.3) | 18 (52.9) | - | - |
Low activity (C) | 7 (8.9) | 4 (8.9) | 3 (8.8) | - | - |
Moderate activity (C) | 14 (17.7) | 7 (15.6) | 7 (20.6) | - | - |
High activity (C) | 16 (20.3) | 10 (22.2) | 6 (17.6) | - | - |
Missing data | 19 (19.4) | 6 | 0 | ||
HLA-B27 | |||||
Positive | 29 (29.9) | 9 (17.6) | 11 (33.3) | 9 (90.0) | 0 (0.0) |
Negative | 68 (70.1) | 42 (82.4) | 22 (66.7) | 1 (10.0) | 3 (100) |
Missing data | 1 (1.1) | - | 1 (3.1) | - | |
ANA | |||||
Positive | 65 (67.7) | 35 (70.0) | 26 (76.5) | 2 (22.2) | 2 (66.7) |
Negative | 31 (32.3) | 15 (30.0) | 8 (23.5) | 7 (77.8) | 1 (33.3) |
Missing data | 2 (2.2) | 1 (2.0) | - | 1 (10.0) | |
Uveitis | |||||
Yes | 20 (20.4) | 11 (21.6) | 7 (20.6) | 2 (20.0) | 0 (0.0) |
No | 78 (79.6) | 40 (78.4) | 27 (79.4) | 8 (80.0) | 3 (100.0) |
TMJ-affected | |||||
Yes | 26 (26.5) | 14 (27.5) | 11 (32.4) | 1 (10.0) | 0 (0.0) |
No | 72 (73.5) | 37 (72.5) | 23 (67.6) | 9 (90.0) | 3 (100.0) |
ESR (mm/1sth), Median (IQR) 5 | |||||
A | 12.0 (5.0–31.0) | 9.0 (5.0–30.0) | 23.0 (8.8–33.3) | 5.0 (2.0–8.0) | 13.0 (9.0–) |
B | 5.0 (2.0–8.0) | 5.0 (2.0–9.0) | 5.0 (2.0–7.0) | 2.0 (2.0–5.0) | 9.0 (5.0–) |
C | 5.0 (2.0–7.0) | 5.0 (2.0–5.0) | 5.0 (2.0–8.0) | 2.0 (2.0–14.0) | - |
D | 5.0 (2.0–7.8) | 5.0 (2.0–7.3) | 5.0 (2.0–8.0) | 4.0 (2.0–6.0) | 7.0 (7.0–) |
CRP (mg/L), Median (IQR) 5 | |||||
A | 1.0 (1.0–7.8) | 1.0 (1.0–5.4) | 4.0 (1.0–23.3) | 1.0 (1.0–4.0) | 1.0 (1.0–) |
B | 1.0 (1.0–1.0) | 1.0 (1.0–1.0) | 1.0 (1.0–1.0) | 1.0 (1.0–1.0) | 1.0 (1.0–1.0) |
C | 1.0 (1.0–1.0) | 1.0 (1.0–1.0) | 1.0 (1.0–1.0) | 1.0 (1.0–3.5) | - |
D | 1.0 (1.0–1.0) | 1.0 (1.0–1.0) | 1.0 (1.0–1.0) | 1.0 (1.0–1.5) | 1.0 (1.0–) |
Joint count (Median, min–max) 6 | |||||
A | 3.0 (0–44) | 2 (1–4) | 5.5 (1–44) | 1 (1–3) | 1.0 (0–2) |
B | 0.0 (0–7) | 0 (0–7) | 0 (0–7) | 0 (1–3) | 0.0 (0) |
C | 0.0 (0–4) | 0 (0–4) | 0 (0–3) | 0 (0–2) | - |
D | 0.0 (0–11) | 0 (0–4) | 0 (0–11) | 0 (0–2) | 0.0 (0–2) |
JADAS 10–CH (Median, IQR) 6 | |||||
A | 8.3 (6.2–13.3) | 7.5 (6.2–9.8) | 13.9 (8.3–22.1) | 4.8 (4.1–5.9) | 3.9 (2.0–) |
B | 2.1 (0.6–4.2) | 2.0 (0.7–3.9) | 2.4 (0.1–4.2) | 3.3 (0.8–6.0) | 3.5 (0.0–) |
C | 0.5 (0.0–1.9) | 0.5 (0.0–2.1) | 1.0 (0.0–1.7) | 0.1 (0.0–5.1) | - |
D | 0.9 (0.0–5.4) | 0.3 (0.0–3.9) | 0.8 (0.0–5.8) | 2.9 (0.4–8.3) | 2.3 (0.0–) |
PGA 6 | |||||
A | 3 (1.0–4.0) | 2 (1.0–3.0) | 5.0 (3.0–7.0) | 1.0 (1.0–2.0) | 2.0 (1.0–) |
B | 0 (0.0–1.0) | 0.5 (0.0–1.0) | 0.0 (0.0–1.4) | 0.5 (0.0–1.0) | 0.0 (0.0–0.0) |
C | 0 (0.0–1.0) | 0.0 (0.0–0.5) | 0.0 (0.0–0.0) | 0.0 (0.0–0.3) | - |
D | 0 (0.0–1.0) | 0.0 (0.0–0.0) | 0.0 (0.0–2.0) | 0.5 (0.0–1.3) | 0.0 (0.0–) |
CHAQ 6 | |||||
A | 0.5 (0.1–1.1) | 0.4 (0.1–0.8) | 0.8 (0.1–1.4) | 0.3 (0.1–0.5) | 0.1 (0.1–0.1) |
B | 0.1 (0.0–0.6) | 0.1 (0.0–0.5) | 0.3 (0.0–1.1) | 0.1 (0.0–0.2) | 0.6 (0.0–) |
C | 0.0 (0.0–0.3) | 0.0 (0.0–0.3) | 0.1 (0.0–0.4) | 0.1 (0.0–0.2) | - |
D | 0.0 (0.0–0.4) | 0.0 (0.0–0.4) | 0.0 (0.0–0.5) | 0.2 (0.0–0.4) | 0.1 (0.0–) |
SNP | Controls 1, n = 99 (%) | Controls 1,2 n = 994 (%) | JIA Patients 3, n = 98 (%) | OR (95% Cl) | p-Value |
---|---|---|---|---|---|
IL-17A | |||||
rs9395767 | |||||
AA | 31 (32.3) | 27 (27.6) | 0.749 | ||
AT | 43 (43.4) | 42 (42.9) | |||
TT | 25 (25.3) | 29 (29.6) | |||
AT + TT 4 | 67 (67.7) | 71 (72.4) | 1.26 (0.68–2.32) | 0.534 | |
A-allele | 105 (53.0) | 96 (49.0) | 1.18 (0.79–1.75) | 0.394 | |
T-allele | 93 (47.0) | 100 (51.0) | |||
HWE (p-value) | 0.211 | 0.158 | |||
rs4711998 | |||||
GG | 47 (47.5) | 41 (41.8) | 0.521 | ||
AG | 45 (45.5) | 46 (46.9) | |||
AA | 7 (7.1) | 11 (11.2) | |||
AG + AA 4 | 52 (52.2) | 57 (58.2) | 1.26 (0.72–2.21) | 0.475 | |
G-allele | 139 (70.2) | 128 (65.3) | 1.25 (0.82–1.91) | 0.299 | |
A-allele | 59 (29.8) | 68 (34.7) | |||
HWE (p-value) | 0.390 | 0.723 | |||
rs8193036 | |||||
TT | 43 (43.0) | 28 (28.6) | 0.089 | ||
CT | 40 (40.4) | 48 (49.0) | |||
CC | 19 (19.2) | 22 (22.4) | |||
CT + CC 4 | 59 (59.6) | 70 (71.4) | 1.92 (1.06–3.47) | 0.038 | |
T-allele | 126 (63.6) | 104 (53.1) | 1.43 (0.96–2.13) | 0.079 | |
C-allele | 78 (36.4) | 92 (46.9) | |||
HWE (p-value) | 0.087 | 0.869 | |||
rs2275913 | |||||
GG | 341 (34.3) | 24 (24.5) | 0.246 | ||
GA | 464 (46.7) | 47 (48.5) | |||
AA | 189 (19.0) | 27 (27.6) | |||
GA + AA 4 | 653 (65.7) | 74 (75.5) | 1.61 (0.99–2.60) | 0.049 * | |
G-allele | 1146 (57.6) | 95 (48.5) | 1.45 (1.08–2.60) | 0.014 * | |
A-allele | 842 (42.4) | 101 (51.5) | |||
HWE (p-value) | 0.165 | 0.692 | |||
IL-10 | |||||
rs1800896 | |||||
TT | 318 (32.5) | 22 (22.4) | 0.076 | ||
TC | 461 (47.1) | 57 (58.2) | |||
CC | 200 (20.4) | 19 (20.9) | |||
TC + CC 4 | 661 (67.5) | 76 (76.9) | 1.66 (1.02–2.72) | 0.042 * | |
T-allele | 1097 (56.0) | 101 (51.5) | 1.20 (0.89–1.61) | 0.228 | |
C-allele | 861 (44.0) | 95 (48.5) | |||
HWE (p-value) | 0.165 | 0.104 | |||
rs1800871 | |||||
GG | 594 (60.4) | 58 (59.2) | 0.076 | ||
GA | 329 (33.5) | 39 (39.8) | |||
AA | 60 (6.1) | 1 (1.0) | |||
GA + AA 3 | 40 (40.4) | 36 (39.6) | 1.06 (0.69–1.61) | 0.810 | |
G-allele | 1517 (76.3) | 145 (74.0) | 0.86 (0.59–1.26) | 0.424 | |
A-allele | 449 (23.7) | 37 (26.0) | |||
HWE (p-value) | 0.114 | 0.045 | |||
rs1800872 | |||||
GG | 594 (60.4) | 55 (60.4) | 0.076 | ||
GT | 329 (33.5) | 35 (38.5) | |||
TT | 60 (6.1) | 1 (1.1) | |||
GT + TT 3 | 40 (40.4) | 36 (39.6) | 1.06 (0.69–1.61) | 0.810 | |
G-allele | 1517 (76.3) | 145 (74.0) | 0.86 (0.59–1.26) | 0.424 | |
T-allele | 449 (23.7) | 37 (26.0) | |||
HWE (p-value) | 0.114 | 0.045 |
SNPs | Controls 1, n = 99 (%) | Controls 1,2 n = 994 (%) | Oligoarthritis, n = 51 (%) | OR (95% Cl), p-Value | Polyarthritis, n = 34 (%) | OR (95% Cl), p-Value | ERA, n = 10 (%) | OR (95% Cl), p-Value |
---|---|---|---|---|---|---|---|---|
IL-17A | ||||||||
rs9395767 | ||||||||
AA | 31 (31.3) | 18 (35.3) | 0.858 | 7 (20.6) | 0.457 | 1 (10.0) | 0.327 | |
AT | 43 (43.4) | 20 (39.2) | 16 (47.1) | 5 (50.0) | ||||
TT | 25 (25.2) | 13 (25.5) | 11 (32.4) | 4 (40.0) | ||||
AT + TT 3 | 68 (68.7) | 33 (64.7) | 0.88 (0.43–1.79), 0.718 | 27 (79.4) | 1.84 (0.73–4.68), 0.275 | 9 (85.7) | 4.30 (0.52–35.40), 0.277 | |
A-allele | 105 (53.0) | 56 (54.9) | 0.93 (0.57–1.50), 0.758 | 30 (44.1) | 1.43 (0.82–2.50), 0.206 | 7 (0.35) | 2.10 (0.80–5.48), 0.131 | |
T-allele | 93 (47.0) | 46 (45.1) | 38 (55.9) | 13 (0.65) | ||||
rs4711998 | ||||||||
GG | 47 (47.5) | 22 (43.1) | 0.608 | 13 (38.2) | 0.643 | 4 (40.0) | 0.367 | |
AG | 45 (45.5) | 23 (45.1) | 18 (52.9) | 4 (40.0) | ||||
AA | 7 (7.1) | 6 (11.8) | 3 (8.8) | 2 (20.0) | ||||
AG + AA 3 | 52 (52.5) | 28 (56.0) | 1.19 (0.603–2.35), 0.730 | 21 (61.8) | 1.46 (0.66–3.24), 0.426 | 6 (60.0) | 1.36 (0.36–5.10), 0.748 | |
G-allele | 139 (70.2) | 67 (65.7) | 1.23 (0.74–2.05), 0.798 | 44 (64.7) | 1.29 (0.72–2.30), 0.843 | 12 (60.0) | 1.57 (0.61–4.04), 0.349 | |
A-allele | 59 (29.8) | 35 (34.3) | 24 (35.3) | 8 (40.0) | ||||
rs8193036 | ||||||||
TT | 40 (40.4) | 15 (29.4) | 0.219 | 10 (29.4) | 0.354 | 3 (30.0) | 0.514 | |
CT | 40 (40.4) | 24 (47.1) | 17 (50.0) | 6 (60.0) | ||||
CC | 19 (16.2) | 12 (23.5) | 7 (20.6) | 1 (10.0) | ||||
CT + CC 3 | 59 (59.6) | 34 (68.0) | 1.84 (0.90–3.79), 0.113 4 | 24 (70.6) | 1.84 (0.80–4.26), 0.162 2 | 7 (70.0) | 1.79 (0.44–7.34), 0.514 | |
T-allele | 126 (63.6) | 54 (52.9) | 1.44 (0.89–2.32), 0.140 | 37 (54.4) | 1.93 (1.11–3.36), 0.020 * | 12 (60.0) | 1.08 (0.42–2.75), 0.155 | |
C-allele | 78 (36.4) | 48 (47.1) | 31 (45.6) | 8 (40.0) | ||||
rs2275913 | ||||||||
GG | 341 (34.3) | 9 (17.6) | 0.046 4 | 8 (23.5) | 0.055 | 5 (50.0) | 0.521 | |
GA | 464 (46.7) | 29 (56.9) | 14 (41.2) | 3 (30.0) | ||||
AA | 189 (19.0) | 13 (25.5) | 12 (35.3) | 2 (20.0) | ||||
GA + AA 3 | 653 (65.7) | 42 (82.4) | 2.44 (1.17–5.07), 0.014 | 26 (76.5) | 1.70 (0.66–3.98), 0.192 | 5 (50.0) | 0.52 (0.15–1.09), 0.299 | |
G-allele | 1146 (57.6) | 47 (46.1) | 1.59 (1.07–2.37), 0.022 5 | 30 (44.1) | 1.72 (1.06–2.81), 0.028 3 | 13 (65.0) | 0.73 (0.29–1.87), 0.509 | |
A-allele | 842 (42.4) | 55 (53.9) | 38 (55.9) | 7 (35.0) | ||||
IL-10 | ||||||||
rs1800896 | ||||||||
TT | 318 (32.5) | 11 (21.6) | 0.200 | 8 (23.5) | 0.387 | 1 (10.0) | 0.266 | |
TC | 461 (47.1) | 30 (58.5) | 20 (58.8) | 7 (70.0) | ||||
CC | 200 (20.4) | 10 (19.6) | 6 (17.6) | 2 (20.0) | ||||
TC + CC 3 | 661 (67.5) | 40 (78.4) | 1.75 (0.89–3.46), 0.103 | 26 (76.5) | 1.56 (0.70–3.49), 0.289 | (90.0) | 4.33 (0.55–34.32), 0.130 | |
T-allele | 1097 (56.0) | 52 (51.0) | 1.23 (0.82–1.82), 0.318 | 36 (52.9) | 1.20 (0.74–2.33), 0.471 | 9 (45.0) | 1.64 (0.68 –3.98), 0.272 | |
C-allele | 861 (44.0) | 50 (49.0) | 32 (47.1) | 11 (55.0) | ||||
rs1800871 | ||||||||
GG | 594 (60.4) | 30 (58.8) | 0.136 | 19 (55.9) | 0.538 | 8 (80.0) | 0.412 | |
GA | 329 (33.5) | 21 (41.2) | 14 (41.2) | 2 (20.0) | ||||
AA | 60 (6.1) | 0 (0.0) | 1 (2.9) | 2 (20.0) | ||||
GA + AA 3 | 40 (40.4) | 21 (41.2) | 1.03 (0.60–1.90), 0.819 | 15 (44.1) | 1.20 (0.61–2.40), 0.894 | 1 (14.4) | 0.38 (0.08–1.81), 0.208 | |
G-allele | 1517 (76.3) | 81 (79.4) | 0.88 (0.54–1.43), 0.597 | 52 (76.5) | 0.99 (0.52–1.89), 0.972 | 18 (90.0) | 1.13 (0.44–2.85), 0.802 | |
A-allele | 449 (23.7) | 21 (20.6) | 16 (23.5) | 6 (10.0) |
SNPs | ANA (%) | OR (95% Cl), p-Value | Uveitis (%) | OR (95% Cl), p-Value | TMJ (%) | OR (95% Cl), p-Value | |||
---|---|---|---|---|---|---|---|---|---|
Positive | Negative | Yes | No | Yes | No | ||||
ALL | 65 (67.7) | 31 (32.3) | 20 (20.4) | 78 (79.6) | 26 (26.5) | 72 (73.5) | |||
Missing cases | 2 (2.0) | - | - | ||||||
IL-17A | |||||||||
rs9395767 | |||||||||
AA | 15 (55.6) | 12 (44.4) | 0.084 2 | 4 (14.8) | 23 (85.2) | 0.220 | 5 (18.5) | 22 (81.5) | 0.400 |
AT | 26 (65.0) | 14 (35.0) | 12 (28.6) | 30 (71.4) | 11 (26.2) | 31 (73.8) | |||
TT | 24 (82.8) | 5 (17.2) | 4 (13.8) | 25 (86.2) | 10 (34.5) | 19 (65.5) | |||
AT + TT 1 | 50 (72.5) | 19 (27.5) | 2.11 (0.84–5.31), 0.111 | 16 (22.5) | 55 (75.5) | 1.52 (0.56–4.14), 0.576 | 21 (29.6) | 50 (70.4) | 1.60 (0.18–1.62), 0.268 |
rs4711998 | |||||||||
GG | 27 (67.5) | 13 (32.5) | 0.255 | 7 (17.1) | 34 (82.9) | 0.363 | 11 (26.8) | 30 (73.2) | 0.792 |
AG | 29 (63.0) | 17 (37) | 9 (19.6) | 37 (80.4) | 13 (28.3) | 33 (71.7) | |||
AA | 9 (90.0) | 1 (10.0) | 4 (36.4) | 7 (63.6) | 2 (18.2) | 9 (81.8) | |||
AG + AA 1 | 38 (67.9) | 18 (32.1) | 1.02 (0.43–2.42), 0.971 | 13 (22.8) | 44 (77.2) | 1.34 (0.59–3.05), 0.487 | 15 (26.3) | 42 (73.7) | 0.98 (0.50–1.91), 0.955 |
rs8193036 | |||||||||
TT | 16 (57.1) | 12 (42.9) | 0.324 | 7 (25.0) | 21 (75.0) | 0.610 | 5 (17.9) | 23 (82.1) | 0.149 |
CT | 33 (70.2) | 14 (29.8) | 10 (20.8) | 38 (79.2) | 17 (35.4) | 31 (64.6) | |||
CC | 16 (76.2) | 5 (23.8) | 3 (13.6) | 19 (86.4) | 4 (18.2) | 18 (81.8) | |||
CT + CC 1 | 49 (72.1) | 19 (27.9) | 1.93 (0.77–4.84), 0.155 | 13 (18.6) | 57 (81.4) | 0.74 (0.33–1.67), 0.476 | 21 (30.0) | 49 (70.0) | 1.68 (0.70–4.02), 0.219 |
rs2275913 | |||||||||
GG | 16 (66.7) | 8 (33.3) | 0.979 | 4 (16.7) | 20 (83.3) | 0.684 | 6 (25.0) | 18 (75.0) | 0.763 |
GA | 31 (67.4) | 15 (32.6) | 9 (19.9) | 38 (80.9) | 14 (29.8) | 33 (70.2) | |||
AA | 18 (69.2) | 8 (30.8) | 7 (25.7) | 20 (74.1) | 6 (22.0) | 21 (77.8) | |||
GA + AA 1 | 49 (68.1) | 23 (31.9) | 1.07 (0.40–2.85), 0.999 | 16 (21.6) | 58 (78.4) | 1.30 (0.22–2.43), 0.601 | 20 (27.0) | 54 (73.0) | 1.08 (0.49–2.38), 0.845 |
IL-10 | |||||||||
rs1800896 | |||||||||
TT | 15 (68.2) | 7 (31.8) | 0.891 | 4 (18.2) | 18 (81.8) | 0.958 | 8 (36.4) | 14 (63.6) | 0.161 |
TC | 38 (69.1) | 17 (30.9) | 12 (21.1) | 45 (78.9) | 16 (28.1) | 41 (71.9) | |||
CC | 12 (63.2) | 7 (36.8) | 4 (21.1) | 15 (78.9) | 2 (10.5) | 17 (89.5) | |||
TC + CC 1 | 50 (67.6) | 24 (32.4) | 0.97 (0.35–2.70), 0.957 | 16 (21.1) | 60 (78.9) | 1.17 (0.43–3.11), 0.769 | 18 (23.7) | 58 (76.3) | 0.65 (0.33–1.29), 0.236 |
rs1800871 | |||||||||
GG | 36 (63.2) | 21 (36.8) | 0.441 | 12 (20.7) | 46 (79.3) | 0.878 | 15 (57.7) | 43 (74.1) | 0.247 |
GA | 28 (73.7) | 10 (26.3) | 8 (20.5) | 31 (79.5) | 10 (38.5) | 29 (74.4) | |||
AA | 1 (100.0) | 0 (0.0) | 0 (0.0) | 1 (100.0) | 1 (100.0) | 0 (0.0) | |||
GA + AA 1 | 29 (74.4) | 10 (25.6) | 1.69 (0.69–4.15), 0.249 | 8 (20.0) | 32 (80.0) | 0.97 (0.44–2.15), 0.934 | 11 (27.5) | 29 (72.5) | 1.06 (0.55–2.07), 0.857 |
Subjects | IL-17A 1 | IL-17F 1 | IL-10 1 | IL-6 1 |
---|---|---|---|---|
All (n = 98) | 1.1 (55.4) | 0.20 (0.78) | 7.57 (47.82) | 131.4 (1953.75) |
Sex | ||||
Male (n = 27) | 1.1 (85.8) | 0.19 (0.94) | 22.61 (49.39) | 193.37 (859.79) |
Female (n = 71) | 1.1 (50.1) | 0.20 (0.66) | 5.11 (44.74) | 111.92 (2235.0) |
p-value | 0.943 | 0.501 | 0.093 | 0.913 |
Subtype | ||||
Oligoarthritis (n = 51) | 1.1 (0.0) | 0.16 (0.45) | 7.01 (30.72) | 39.06 (2235.00) |
Polyarthritis (n = 34) | 1.1 (231.33) | 0.37 (1.15) | 8.61 (75.53) | 264.24 (9706.65) |
ERA (n = 10) | 1.1 (138.48) | 0.19 (0.50) | 30.87 (51.27) | 38.27 (20.49) |
p-value | 0.227 | 0.348 | 0.204 | 0.259 |
Activity 2 | ||||
Inactive (n = 42) | 1.10 (35.02) | 0.30 (0.78) | 2.63 (29.63) | 69.88 (1555.32) |
Low (n = 7) | 1.10 (85.80) | 0.33 (2.32) | 18.84 (94.81) | 388.65 (3368.15) |
Median (n = 14) | 1.10 (174.03) | 0.31 (6.03) | 53.00 (98.02) | 195.58 (10650.24) |
High (n = 16) | ||||
p-value | 0.742 | 0.012 | 0.006 | 0.549 |
SNP | Number of Subjects | IL-17A 1 | IL-17F 1 | IL-10 1 | IL-6 1 |
---|---|---|---|---|---|
IL-17A | |||||
rs9395767 | |||||
AA | 27 | 1.10 (50.10) | 0.17 (0.45) | 0.15 (47.3) | 838.58 (11445.0) |
AT | 42 | 1.10 (27.07) | 0.18 (0.48) | 6.0 (30.29) | 64.33 (1283.75) |
TT | 29 | 1.1 (277.25) | 0.36 (2.31) | 22.72 (96.72) | 134.23 (728.55) |
p-value | 0.293 | 0.030 2 | 0.088 | 0.243 | |
rs4711998 | |||||
GG | 41 | 1.10 (0.00) | 0.11 (0.30) | 0.15 (30.29) | 111.92 (1595.21) |
AG | 46 | 1.10 (246.24) | 0.33 (0.87) | 11.39 (52.42) | 187.39 (3539.56) |
AA | 11 | 1.10 (89.39) | 0.26 (1.61) | 6.83 (94.81) | 67.95 (3912.00) |
p-value | 0.063 1 | 0.010 3 | 0.337 | 0.910 | |
rs8193036 | |||||
TT | 28 | 1.10 (22.49) | 0.13 (0.68) | 4.05 (29.70) | 120.46 (1595.00) |
CT | 48 | 1.10 (82.19) | 0.24 (1.58) | 6.92 (77.77) | 47.32 (1451.57) |
CC | 22 | 1.10 (167.55) | 0.20 (0.36) | 14.90 (48.21) | 316.71 (10693.61) |
p-value | 0.390 | 0.248 | 0.563 | 0.287 | |
rs2275913 | |||||
GG | 24 | 1.10 (147.43) | 0.36 (0.90) | 9.50 (42.31) | 28.76 (236.69) |
AG | 47 | 1.10 (50.10) | 0.21 (0.68) | 10.24 (50.92) | 347.93 (1860.00) |
AA | 27 | 1.10 (45.68) | 0.12 (0.82) | 6.64 (56.90) | 133.78 (9685.00) |
p-value | 0.881 | 0.123 | 0.776 | 0.277 | |
IL-10 | |||||
rs1800896 | |||||
TT | 22 | 6.80 (197.69) | 0.54 (3.09) | 37.88 (110.90) | 243.65 (9923.23) |
TC | 57 | 1.10 (28.28) | 0.19 (0.48) | 6.83 (31.59) | 67.95 (1562.00) |
CC | 19 | 1.10 (85.80) | 0.07 (0.36) | 0.15 (142.02) | 337.71 (1860.00) |
p-value | 0.189 | 0.021 4 | 0.125 | 0.406 | |
rs1800871 | |||||
GG | 58 | 1.10 (86.70) | 0.19 (1.48) | 12.69 (58.71) | 131.39 (1578.82) |
GA | 39 | 1.10 (29.99) | 0.21 (0.76) | 6.83 (22.46) | 108.64 (6605.00) |
AA | 1 | ||||
p-value | 0.735 | 0.673 | 0.307 | 0.873 |
Target | Primers | Annealing Temperature (°C) | PCR Product Size (bp) |
---|---|---|---|
IL-17A | |||
rs147789086 2 | F: 5′-TGTGCACTAGGTGGAGGAAAC-3′ R: 5′-CCAGCACACAAGGAGCAATG-3′ 1 | 60 | 724 |
rs9395767 | |||
rs2275913 | F: 5′-TGACCCATAGCATAGCAGCTC-3′ 1 R: 5′-TCTTGTGTGGTTTAGCCCCAA-3′ | 60 | 576 |
rs8193037 2 | |||
rs3819025 2 | |||
rs8193038 2 | |||
rs8193036 | F: 5′-GGGCGGAGAAGGGTGACATA-3′ 1 R: 5′-GATTCCTTGGCCAGGTGTTGT-3′ | 60 | 521 |
rs4711998 | |||
IL-10 | |||
rs1800896 | F: 5′-CCAGATATCTGAAGAAGTCCTG-3′ R: 5′-CCTAGGTCACAGTGACGTGG-3′ 1 | 55 | 901 |
rs1800871 | |||
rs1800872 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Möttönen, M.; Teräsjärvi, J.; Rahikkala, H.; Kvist, S.; Mertsola, J.; He, Q. Association of IL-17A and IL-10 Polymorphisms with Juvenile Idiopathic Arthritis in Finnish Children. Int. J. Mol. Sci. 2024, 25, 8323. https://doi.org/10.3390/ijms25158323
Möttönen M, Teräsjärvi J, Rahikkala H, Kvist S, Mertsola J, He Q. Association of IL-17A and IL-10 Polymorphisms with Juvenile Idiopathic Arthritis in Finnish Children. International Journal of Molecular Sciences. 2024; 25(15):8323. https://doi.org/10.3390/ijms25158323
Chicago/Turabian StyleMöttönen, Milja, Johanna Teräsjärvi, Heidi Rahikkala, Sonja Kvist, Jussi Mertsola, and Qiushui He. 2024. "Association of IL-17A and IL-10 Polymorphisms with Juvenile Idiopathic Arthritis in Finnish Children" International Journal of Molecular Sciences 25, no. 15: 8323. https://doi.org/10.3390/ijms25158323